Concurrently, LATS2 expression in the tumor tissues of the Exo-A375-NC inhibitor group decreased relative to the PBS control group, while the co-administration of miR-424-5p inhibitor increased LATS2 levels (Fig. 5C). Here, LATS2 is linked to neoplasm.